Study Correction Flags Adherence Issues With Breast Cancer Drug Combo

A correction to a major breast cancer trial reveals new concerns about how well patients stick with treatment when palbociclib is added to hormone therapy. The finding matters to drug makers, insurers, and hospitals because poor adherence undermines clinical benefits and drives up real-world treatment costs.

Originaltitel: Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer